Neurogene (NGNE) Depreciation & Amortization (CF) (2013 - 2026)
Neurogene (NGNE) reported Depreciation & Amortization (CF) of $847000.0 for Q1 2026, up 13.08% on a YoY basis from $749000.0 in Q1 2025, and up 15.55% quarter-over-quarter from $733000.0 in Q4 2025.
Neurogene (NGNE) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Neurogene has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $847000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 13.08% year-over-year to $847000.0; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 0.98% YoY), and the FY2025 full-year result was $3.0 million, down 6.25% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $847000.0, up from $733000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $2.0 million in Q4 2022, with the low at $323000.0 in Q3 2022.
- Historically, Depreciation & Amortization (CF) has averaged $797411.8 across 5 years, with a median of $800000.0 in 2023.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 413.59% — and 2023, when it sank 59.21%.
- Neurogene's Depreciation & Amortization (CF) stood at $2.0 million in 2022, then slumped by 59.21% to $817000.0 in 2023, then declined by 2.08% to $800000.0 in 2024, then declined by 8.38% to $733000.0 in 2025, then advanced by 15.55% to $847000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $847000.0 (Q1 2026), $733000.0 (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | 847,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 847,000.00 |
| Mar 31, 2026 | 847,000.00 |
| Dec 31, 2025 | 733,000.00 |
| Dec 31, 2025 | 733,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 749,000.00 |
| Mar 31, 2025 | 749,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Mar 31, 2024 | 814,000.00 |
| Mar 31, 2024 | 814,000.00 |
| Dec 31, 2023 | 817,000.00 |
| Dec 31, 2023 | 817,000.00 |